## Sangamo Therapeutics’ Gene Therapy for Fabry Disease Gets FDA Fast Track Approval, Stock Soars 33%
The news sent ripples through the market today as Sangamo Therapeutics, Inc. (SGMO) witnessed its stock price skyrocket by over 33%. The catalyst behind this surge? The U.S. Food and Drug Administration (FDA) granted an accelerated pathway for ST-920, Sangamo’s potential gene therapy for the treatment of Fabry disease.
This FDA approval marks a significant milestone for Sangamo. It allows the company to bypass an additional study that would have otherwise been required, potentially accelerating the drug’s approval by a remarkable three years. This swift timeline is made possible by the promising results from the ongoing Phase 1/2 STAAR study, which demonstrated encouraging safety and efficacy data, particularly in relation to improved kidney function.
Fabry disease is a debilitating genetic disorder that can lead to a range of complications, including kidney failure. The positive data from the STAAR study suggests that ST-920 could effectively address these renal issues, offering hope to patients grappling with this challenging condition. The study showed evidence of improved estimated glomerular filtration rate (eGFR), a key indicator of kidney function, highlighting the therapeutic potential of ST-920 in mitigating the long-term consequences of Fabry disease.
“Fabry is a debilitating disease, for which there is a serious unmet medical need,” emphasized Sandy Macrae, CEO of Sangamo. “I strongly believe in the potential for ST-920 to alleviate many manifestations of Fabry disease and am delighted to have a clear regulatory pathway that could bring this treatment to patients significantly sooner than originally anticipated.”
With the FDA’s fast track approval secured, Sangamo is now gearing up for the next stage. The company has initiated Biologics License Application (BLA) readiness activities and anticipates submitting the BLA during the second half of 2025. This strategic move positions Sangamo to potentially bring ST-920 to market within the next two years, offering much-needed hope to patients battling Fabry disease.
How to Invest in Sangamo Therapeutics Stock:
Investors seeking to participate in the potential of Sangamo Therapeutics can access shares through various avenues:
*
Brokerage Platforms:
Purchase individual shares or fractional shares directly through online brokerage platforms.*
Exchange Traded Funds (ETFs):
Invest in ETFs that hold shares of Sangamo Therapeutics. This approach offers diversification by including other healthcare companies within the portfolio.*
401(k) Strategies:
Allocate a portion of your retirement savings to a strategy that invests in mutual funds or other instruments that hold shares of Sangamo Therapeutics.Sangamo Therapeutics operates within the healthcare sector, and investing in ETFs or 401(k) strategies focused on this sector provides exposure to a broader range of healthcare companies and trends.